Loading...
Cladribine monotherapy yields a high response rate and durable remission for most patients with hairy cell leukemia (HCL), usually with only one treatment cycle. Varying treatment schedules have been employed, including 7-day continuous infusion, daily 2-hour infusions for 5 days, and weekly 2-hour infusions for 6 weeks; some reports have suggested that fewer treatment-related complications occur with the once-weekly schedule. The Polish Adult Leukemia Group conducted a randomized prospective comparison of two cladribine regimens in 116 previously untreated HCL patients: 0.12 mg/kg during 2 hours daily for 5 consecutive days, or the same dose and infusion time once weekly for 6 weeks. Patients with complete responses (CRs) received no furth…